無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

COPDおよび喘息装置の世界市場:吸入器タイプ別 (散剤、定量、ソフトミスト) 、ネブライザー別 (コンプレッサー、超音波、メッシュ) - 市場機会分析および業界予測

COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015 - 2022

発行 Allied Market Research 商品コード 370258
出版日 ページ情報 英文 158 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.47円で換算しております。
Back to Top
COPDおよび喘息装置の世界市場:吸入器タイプ別 (散剤、定量、ソフトミスト) 、ネブライザー別 (コンプレッサー、超音波、メッシュ) - 市場機会分析および業界予測 COPD and Asthma Devices Market by Inhalers Type (Drug powder, Metered Dose, Soft Mist), Nebulizers (Compressor, Ultrasonic, Mesh) - Global Opportunity Analysis and Industry Forecasts, 2015 - 2022
出版日: 2016年08月01日 ページ情報: 英文 158 Pages
概要

世界のCOPDおよび喘息装置市場は2022年までに413億5,520万米ドルに達すると予測されています。市場成長を牽引しているのが、喘息などの呼吸器疾患に対する意識の向上と喫煙などが原因となる呼吸器疾患の発症率上昇です。

当レポートでは、世界のCOPDおよび喘息装置市場について調査し、市場の製品別動向と地域別動向、2015〜2022年の予測、および市場に参入する企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
  • ポーターズファイブフォース分析
  • バリューチェーン分析
  • 市場シェア分析
  • 政府の法規制
  • 促進因子
  • 阻害因子
  • 機会

第4章 製品別市場

  • 吸入器
    • 散剤式
    • 定量式
    • ソフトミスト式
  • ネブライザー
    • コンプレッサーネブライザー
    • 超音波ネブライザー
    • メッシュネブライザー

第5章 地域別市場

  • イントロダクション
  • 市場規模と予測
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第6章 企業プロファイル

  • Glaxosmithcline PLC
  • Novartis AG
  • Merck & Company
  • Philips Healthcare (Division of Royal Philips Company)
  • AstraZeneca Plc.
  • 3M Healthcare
  • GF Health Products
  • Sunovion Pharmaceuticals Inc.
  • Smith Medicals, Inc.
  • Baxter International
  • Boehringer Ingelheim GmbH

図表

図表

List of Tables

  • TABLE 1 WORLD COPD AND ASTHMA DEVICES MARKET, MODERATE GROWTH SCENARIO BY GEOGRAPHY, 20222027 ($MILLION)
  • TABLE 2 WORLD COPD AND ASTHMA DEVICES MARKET, RAPID GROWTH SCENARIO BY GEOGRAPHY, 20222027 ($MILLION)
  • TABLE 3 WORLD COPD AND ASTHMA DEVICES MARKET, DIMINISHING GROWTH SCENARIO BY GEOGRAPHY, 20222027 ($MILLION)
  • TABLE 4 ADVANTAGES AND DISADVANTAGES OF MARKETED PORTABLE INHALER DEVICES
  • TABLE 5 PERCENTAGE OF SMOKER POPULATION BY ETHNICITY, 2012
  • TABLE 6 TOP 10 COUNTRIES HEALTHCARE EXPENDITURE, 2013
  • TABLE 7 WORLD COPD AND ASTHMA DEVICES MARKET, BY PRODUCT TYPE, 20152022, ($MILLION)
  • TABLE 8 RESCUE INHALERS VS MAINTENANCE INHALERS
  • TABLE 9 COMMON TYPES OF INHALERS
  • TABLE 10 TOP 10 COPD INHALERS
  • TABLE 11 WORLD COPD AND ASTHMA INHALERS MARKET, BY TYPE, 2015-2022, ($MILLION)
  • TABLE 12 WORLD COPD AND ASTHMA INHALERS MARKET, BY GEOGRAPHY, 2015-2022, ($MILLION)
  • TABLE 13 DRY POWDER INHALERS
  • TABLE 14 WORLD DRY POWDER INHALERS (DPI) MARKET, BY GEOGRAPHY, 20152022, $MILLION
  • TABLE 15 TYPES OF METERED DOSE INHALERS (MDIS)
  • TABLE 16 WORLD METERED DOSE INHALERS (MDI) MARKET, BY GEOGRAPHY, 20152022, $MILLION
  • TABLE 17 WORLD SOFT MIST INHALERS (SMI) MARKET, BY GEOGRAPHY,
  • TABLE 18 2015-2022, $MILLION
  • TABLE 19 COMMERCIALIZED NEBULIZERS AND ITS COST
  • TABLE 20 WORLD NEBULIZERS MARKET, BY TYPE, 20152022, ($MILLION)
  • TABLE 21 WORLD NEBULIZERS MARKET, BY GEOGRAPHY, 2015-2022, ($MILLION)
  • TABLE 22 WORLD COMPRESSOR NEBULIZERS MARKET, BY GEOGRAPHY, 2015-2022, ($MILLION)
  • TABLE 23 WORLD ULTRASONIC NEBULIZERS MARKET, BY GEOGRAPHY, 20152022, ($MILLION)
  • TABLE 24 WORLD MESH NEBULIZERS MARKET, BY GEOGRAPHY, 20152022, ($MILLION)
  • TABLE 25 WORLD COPD AND ASTHMA DEVICES MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
  • TABLE 26 NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY TYPE, 2015-2022 ($MILLION)
  • TABLE 27 EUROPE COPD AND ASTHMA DEVICES MARKET, BY TYPE; 20152022 ($MILLION)
  • TABLE 28 ASIA-PACIFIC COPD DEVICES MARKET, BY TYPE, 2015-2022 ($MILLION)
  • TABLE 29 LAMEA COPD AND ASTHMA MARKET, BY TYPE, 2015-2022 ($MILLION)
  • TABLE 30 GLAXOSMITHKLINE PLC SNAPSHOT
  • TABLE 31 GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
  • TABLE 32 NOVARTIS AG SNAPSHOT
  • TABLE 33 NOVARTIS AG OPERATING SEGEMENTS
  • TABLE 34 MERCK COMPANY SNAPSHOT
  • TABLE 35 MERCK OPERATING SEGEMENTS
  • TABLE 36 PHILIPS HEALTHCARE BUSINESS SNAPSHOT
  • TABLE 37 ASTRAZENECA INC. SNAPSHOT
  • TABLE 38 ASTRAZENACA INC. OPERATING SEGMENT OVERVIEW
  • TABLE 39 3M SNAPSHOT
  • TABLE 40 GF HEALTH PRODUCTS SNAPSHOT
  • TABLE 41 SUNOVION SNAPSHOT
  • TABLE 42 SUNOVION OPERATING SEGEMENTS
  • TABLE 43 SMITH MEDICAL INC SNAPSHOT
  • TABLE 44 BAXTER SNAPSHOT
  • TABLE 45 BOEHRINGER INGELHEIM GMBH SNAPSHOT
  • TABLE 46 BOEHRINGER INGELHEIM GMBH OPERATING SEGEMENTS

List of Figures

  • FIG. 1 IMPACT ANALYSIS OF MODERATE GROWTH SCENARIO, 2022-2027
  • FIG. 2 IMPACT ANALYSIS OF RAPID GROWTH SCENARIO, 20222027
  • FIG. 3 IMPACT ANALYSIS OF DIMINISHING GROWTH SCENARIO, 20222027
  • FIG. 4 TOP FACTORS IMPACTING WORLD COPD AND ASTHMA DEVICES MARKET, 20152022
  • FIG. 5 TOP INVESTMENT POCKETS OF WORLD COPD AND ASTHMA DEVICES MARKET, BY PRODUCT TYPES
  • FIG. 6 TOP WINNING STRATEGY IN COPD AND ASTHMA DEVICES MARKET, 20122016
  • FIG. 7 TOP WINNING STRATEGIES, BY APPLICATION, 20122016
  • FIG. 8 PORTERS FIVE FORCES ANALYSIS OF WORLD COPD AND ASTHMA DEVICES MARKET
  • FIG. 9 VALUE CHAIN ANALYSIS OF WORLD COPD AND ASTHMA DEVICES
  • FIG. 10 MARKET SHARE ANALYSIS OF COPD AND ASTHMA DEVICES MARKET, 2015 (%)
  • FIG. 11 COPD AND ASTHMA INCIDENCE IN GREAT BRITAIN, 2003-2013
  • FIG. 12 U.S. ASTHMA AND COPD DEVICES MARKET, 20152022 ($MILLION)
  • FIG. 13 CANADA COPD AND ASTHMA DEVICES MARKET, 20152022 ($MILLION)
  • FIG. 14 MEXICO COPD AND ASTHMA DEVICES MARKET, 20152022 ($MILLION)
  • FIG. 15 UK COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 16 FRANCE COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 17 GERMANY COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 18 ITALY COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 19 RUSSIA COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 20 REST OF EUROPEAN COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 21 INDIA COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 22 CHINA COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 23 JAPAN COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 24 AUSTRALIA COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 25 REST OF APAC COPD AND ASTHMA DEVICES MARKET, 2015-2022 ($MILLION)
  • FIG. 26 BRAZIL COPD AND ASTHMA MARKET, 20152022 ($MILLION)
  • FIG. 27 ARGENTINA COPD AND ASTHMA MARKET, 20152022 ($MILLION)
  • FIG. 28 COLOMBIA COPD AND ASTHMA MARKET, 20152022 ($MILLION)
  • FIG. 29 SAUDI ARABIA COPD AND ASTHMA MARKET, 20152022 ($MILLION)
  • FIG. 30 TURKEY COPD AND ASTHMA MARKET, 20152022 ($MILLION)
  • FIG. 31 OTHERS COPD AND ASTHMA MARKET, 20152022 ($MILLION)
  • FIG. 32 GLAXOSMITHKLINE PLC, REVENUE 2013-2015 ($MILLION)
  • FIG. 33 GLAXOSMITHKLINE PLC, REVENUE BY GEOGRAPHY 2015 (%)
  • FIG. 34 GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 35 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
  • FIG. 36 NOVARTIS AG REVENUE 2013-2015 ($MILLION)
  • FIG. 37 NOVARTIS AG REVENUE BY GEOGRAPHY, 2015 (%)
  • FIG. 38 NOVARTIS AG REVENUE BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 39 SWOT ANALYSIS OF NOVARTIS AG
  • FIG. 40 MERCK & CO. REVENUE, 2013-2015 ($MILLION)
  • FIG. 41 MERCK REVENUE BY GEOGRAPHY, 2015 (%)
  • FIG. 42 MERCK REVENUE BY BUSINESS UNITS, 2015 (%)
  • FIG. 43 SWOT ANALYSIS OF MERCK
  • FIG. 44 PHILIPS REVENUE, 2013-2015, ($MILLION)
  • FIG. 45 PHILIPS REVENUE, BY BUSINESS UNITS, 2015 (%)
  • FIG. 46 SWOT ANALYSIS OF PHILIPS HEALTHCARE
  • FIG. 47 ASTRAZENECA INC REVENUE, 2013-2015 ($MILLION)
  • FIG. 48 ASTRAZENECA REVENUE, BY SEGMENT 2015 (%)
  • FIG. 49 ASTRAZENECA REVENUYE BY GEOGRAPHY, 2013 (%)
  • FIG. 50 ASTRAZENECA INC. SWOT ANALYSIS
  • FIG. 51 3M REVENUE, 2013-2015 ($MILLION)
  • FIG. 52 3M REVENUE BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 53 3M REVENUE BY GEOGRAPHY, 2015 (%)
  • FIG. 54 SWOT ANALYSIS OF 3M
  • FIG. 55 SWOT ANALYSIS OF GF HEALTH PRODUCTS
  • FIG. 56 SUNOVION REVENUE, 2012-2015 ($MILLION)
  • FIG. 57 SUNOVION REVENUE BY GEOGRAPHY, 2015 (%)
  • FIG. 58 SWOT ANALYSIS OF SUNOVION INC.
  • FIG. 59 SMITH MEDICAL INC. REVENUE, 2013-2015 ($MILLION)
  • FIG. 60 SMITH MEDICAL INC. REVENUE BY GEOGRAPHY, 2015 (%)
  • FIG. 61 SMITH MEDICAL INC- SWOT ANALYSIS
  • FIG. 62 BAXTER INTERNATIONAL REVENUE, 2013-2015 ($MILLION)
  • FIG. 63 BAXTER INTERNATIONAL REVENUE BY GEOGRAPHY, 2015 (%)
  • FIG. 64 BAXTER INTERNATIONAL REVENUE BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 65 SWOT ANALYSIS OF BAXTER INTERNATIONAL
  • FIG. 66 BOEHRINGER INGELHEIM REVENUE, 2013-2015 ($MILLION)
  • FIG. 67 BOEHRINGER INGELHEIM REVENUE BY GEOGRAPHY, 2015 (%)
  • FIG. 68 BOEHRINGER INGELHEIM REVENUE BY BUSINESS SEGMENTS, 2015 (%)
  • FIG. 69 SWOT ANALYSIS OF BOEHRINGER INGELHEIM GMBH
目次
Product Code: LI 16579

COPD and asthma devices, also known as pulmonary drug delivery devices, are used as a permanent treatment or rescue therapy for respiratory diseases and other related ailments. It is the most advanced mode of drug administration in which the drug is directly delivered to the lungs to provide a systemic effect. COPD and asthma have significant shares in the global respiratory diseases market. According to the Global Initiative for Asthma (GINA), around 300 million people across the world suffer from asthma every year. COPD, being the 3rd leading cause for death, led to the death of 3 million people in 2013. Thus, a variety of drug-delivery protocols, such as oral and parenteral delivery, are developed for the treatment of COPD and asthma. However, the pulmonary drug delivery system is the most effective treatment option as compared to the other conventional methods.

The world COPD and asthma devices market is expected to reach $41,355.2 million by 2022. The major factors driving the market growth include increasing awareness for respiratory diseases, such as asthma and emphysema, and rising incidence of respiratory diseases caused due to cigarette consumption. The growth of the market would be boosted due to increase in healthcare expenditure, growth in the use of automation in healthcare industry, and rapid adoption of advanced medical solutions. Currently, most of healthcare practitioners and pulmonary diseases specialists prefer a combination of a drug and a device, for instance inhaler and nebulizer, owing to its fast and effective outcome. However, the market growth could be hindered due to high cost associated with nebulizers, side effects occurring due to excessive dosage, and lack of awareness regarding drug inhalation.

The world COPD and asthma devices market is segmented based on product device type and geography. Based on the product device type, the market is segmented into inhalers and nebulizers. Inhalers segment is projected to grow at a CGAR of 5.3% during the study period. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). The nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. Based on geography, the market is categorized into North America, Europe, Asia-Pacific, and LAMEA. These regions are further analyzed on the basis of respective countries. Within Europe region, Germany, France and U.K. accounted for more than 40% of market share in 2015.

The leading players profiled in this report include GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Philips Healthcare, 3M Health Care, Allied Healthcare Products, Inc., Sunovion Pharmaceuticals, Inc., Boehringer Ingelheim, GF Healthcare Products, Omron Corporation, Smith Medicals, Lincare Holdings, Inc., and Baxter International.

KEY BENEFITS

  • The market estimations in this report are based on high-end analysis of the key segments from 2015 to 2022.
  • Extensive analysis of the world COPD and asthma devices market, by product, helps in understanding the various types of devices used for the treatment of respiratory conditions.
  • This report provides comprehensive analysis of factors that drive and restrict growth of the COPD and asthma devices market.
  • Porter's Five Forces model provides an in-depth analysis of the bargaining power of buyers and suppliers, threats of new entrants and substitutes, and competition among the key market players.
  • Competitive intelligence highlights the business practices adopted by leading market players across various geographies.
  • SWOT analyses of market players enable the study of the internal environment and strategies adopted by them.
  • COPD AND ASTHMA DEVICES MARKET SEGMENTATION
  • The COPD and asthma devices market is segmented based on product type and geography.

By Product Types

  • Inhalers
  • Drug powder inhalers (DPIs)
  • Metered dose inhalers (MDIs)
  • Soft mist inhalers (SMIs)
  • Nebulizers
  • Compressor nebulizers
  • Ultrasonic nebulizers
  • Mesh nebulizers

By Geography

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Russia
  • Others
  • Asia-Pacific
  • India
  • China
  • Japan
  • Australia
  • Others
  • LAMEA
  • Brazil
  • Argentina
  • Colombia
  • Saudi Arabia
  • Turkey
  • Others

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1 Report description
  • 1.2 Key benefits
  • 1.3 Key market segments
  • 1.4 Research methodology
    • 1.4.1 Primary research
    • 1.4.2 Secondary Research
    • 1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1 CXO perspective
  • 2.2 Market beyond what to expect by 2027
    • 2.2.1 Moderate growth scenario
    • 2.2.2 Rapid growth scenario
    • 2.2.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW

  • 3.1 Market definition and scope
  • 3.2 Key findings
    • 3.2.1 Top impacting factors
    • 3.2.2 Top investment pockets
    • 3.2.3 Top winning strategies
  • 3.3 Porters five forces analysis
    • 3.3.1 Bargaining power of buyers (High)
    • 3.3.2 Bargaining power of suppliers (Low to Moderate)
    • 3.3.3 Threat of new entrants (Low)
    • 3.3.4 Threat of substitutes (High)
    • 3.3.5 Intense competitive rivalry
  • 3.4 Value chain analysis
  • 3.5 Market share analysis, 2015
  • 3.6 Government regulations
    • 3.6.1 COPD devices regulations in Europe and in the U.S.
    • 3.6.2 COPD devices regulations in Asia-Pacific
  • 3.7 Drivers
    • 3.7.1 Daily exposure to environmental pollution
    • 3.7.2 Increase in population susceptible to indoor air pollutants
    • 3.7.3 Portability of the drug delivery devices
    • 3.7.4 Increasing population of Active smokers
    • 3.7.5 Rising government initiatives
  • 3.8 Restraints
    • 3.8.1 Increasing price competition and deterioration of material quality
    • 3.8.2 Overall high cost of asthma treatment is a challenge for the patients
    • 3.8.3 Incompetent reimbursement support
  • 3.9 Opportunities
    • 3.9.1 Patent expiration for blockbuster drugs
    • 3.9.2 Soft Mist Inhalers (SMIs): future growth driver

CHAPTER 4 WORLD COPD AND ASTHMA DEVICES MARKET, BY PRODUCT TYPE

  • 4.1 Inhalers
    • 4.1.1 Drug powdered inhalers (DPIs)
      • 4.1.1.1 Key market trends
      • 4.1.1.2 Key growth factors
      • 4.1.1.3 Market size and forecast
    • 4.1.2 Metered dose inhalers (MDIs)
      • 4.1.2.1 Key market trends
      • 4.1.2.2 Key growth factors
      • 4.1.2.3 Market size and forecast
    • 4.1.3 Soft mist inhalers
      • 4.1.3.1 Key market trends
      • 4.1.3.2 Key growth factors
      • 4.1.3.3 Market size and forecast
  • 4.2 Nebulizers
    • 4.2.1 Compressor nebulizers
    • 4.2.2 Ultrasonic nebulizers
    • 4.2.3 Mesh nebulizers

CHAPTER 5 WORLD COPD & ASTHMA DEVICE MARKET, BY GEOGRAPHY

  • 5.1 Introduction
  • 5.2 Market size and forecast
  • 5.3 North America
    • 5.3.1 Key market trends
    • 5.3.2 Market size and forecast
    • 5.3.3 U.S
      • 5.3.3.1 Market size and forecast
    • 5.3.4 Canada
      • 5.3.4.1 Market size and forecast
    • 5.3.5 Mexico
      • 5.3.5.1 Market size and forecast
  • 5.4 Europe
    • 5.4.1 Key market trends
    • 5.4.2 Market size and forecast
    • 5.4.3 UK
      • 5.4.3.1 Market size and forecast
    • 5.4.4 France
      • 5.4.4.1 Market size and forecast
    • 5.4.5 Germany
      • 5.4.5.1 Market size and forecast
    • 5.4.6 Italy
      • 5.4.6.1 Market size and forecast
    • 5.4.7 Russia
      • 5.4.7.1 Market size and forecast
    • 5.4.8 Others European countries
      • 5.4.8.1 Market size and forecast
  • 5.5 Asia-Pacific
    • 5.5.1 Key market trends
    • 5.5.2 Key growth factors and opportunities
    • 5.5.3 Market size and forecast
    • 5.5.4 India
      • 5.5.4.1 Market size and forecast
    • 5.5.5 China
      • 5.5.5.1 Market size and forecast
    • 5.5.6 Japan
      • 5.5.6.1 Market size and forecast
    • 5.5.7 Australia
      • 5.5.7.1 Market size and forecast
    • 5.5.1 Others
      • 5.5.1.1 Market size and forecast
  • 5.6 LAMEA
    • 5.6.1 Key market trends
    • 5.6.2 Market size and forecast
    • 5.6.3 Brazil
      • 5.6.3.1 Market size and forecast
    • 5.6.4 Argentina
      • 5.6.4.1 Market size and forecast
    • 5.6.5 Colombia
      • 5.6.5.1 Market size and forecast
    • 5.6.6 Saudi Arabia
      • 5.6.6.1 Market size and forecast
    • 5.6.7 Turkey
      • 5.6.7.1 Market size and forecast
    • 5.6.8 Others
      • 5.6.8.1 Market size and forecast

CHAPTER 6 COMPANY PROFILES

  • 6.1 Glaxosmithcline PLC
    • 6.1.1 Company overview
    • 6.1.2 Operating business segment overview
    • 6.1.3 Business performance
    • 6.1.4 Key strategies move and development
    • 6.1.5 SWOT analysis
  • 6.2 Novartis AG
    • 6.2.1 Company overview
    • 6.2.2 Operating business segment overview
    • 6.2.3 Business performance
    • 6.2.4 Key strategies and development
    • 6.2.5 SWOT analysis
  • 6.3 Merck & Company
    • 6.3.1 Operating business segment overview
    • 6.3.2 Business performance
    • 6.3.3 SWOT analysis
  • 6.4 Philips Healthcare (Division of Royal Philips Company)
    • 6.4.1 Company overview
    • 6.4.2 Business performance
    • 6.4.3 Strategic moves and developments
    • 6.4.4 SWOT analysis
  • 6.5 AstraZeneca Plc.
    • 6.5.1 Company overview
    • 6.5.2 Operating business segment overview
    • 6.5.3 Business performance
    • 6.5.4 Strategic moves and developments
    • 6.5.5 SWOT analysis
  • 6.6 3M Healthcare
    • 6.6.1 Company overview
    • 6.6.2 Business performance
    • 6.6.3 Strategy move and development
    • 6.6.4 SWOT analysis
  • 6.7 GF Health Products
    • 6.7.1 Company overview
    • 6.7.2 Strategic moves and developments
    • 6.7.3 SWOT analysis
  • 6.8 Sunovion Pharmaceuticals Inc.
    • 6.8.1 Company overview
    • 6.8.2 Operating business segment overview
    • 6.8.3 Business performance
    • 6.8.4 Strategic moves and developments
    • 6.8.5 SWOT analysis
  • 6.9 Smith Medicals, Inc.
    • 6.9.1 Company overview
    • 6.9.2 Business performance
    • 6.9.3 SWOT analysis
  • 6.10 Baxter International
    • 6.10.1 Company overview
    • 6.10.2 Operating business segment overview
    • 6.10.3 Business performance
    • 6.10.4 SWOT analysis
  • 6.11 Boehringer Ingelheim GmbH
    • 6.11.1 Company overview
    • 6.11.2 Operating business segment overview
    • 6.11.3 Business performance
    • 6.11.4 Key strategies and developments
    • 6.11.5 SWOT analysis
Back to Top